Ticker: ANIX

Anixa Biosciences, Inc. (NASDAQ: ANIX) Quick take: Anixa remains a pre-revenue biotech advancing cancer vaccines and a CAR‑T therapeutic. The company cut operating spending versus prior periods and retains roughly $16.0M in cash and short‑term investments, but continues to report operating losses...

ANIXA BIOSCIENCES, INC. (NASDAQ: ANIX) has released its quarterly report for the period ending April 30, 2025, revealing a mix of financial and operational developments. Key Financial Highlights: Revenue: Zero revenue reported for both Q2 2025 and Q2 2024. Net Loss: Q2 2025: $(2.81) million vs....

Anixa Biosciences, Inc. (NASDAQ: ANIX) has released its quarterly financial report for the period ending January 31, 2025. The report highlights both positive and negative aspects of the company's income statement. Key Financial Highlights: No revenue generated in the last two quarters (Q1 2025 ...